Genetic Biomarkers in Saliva Samples From Patients With Ewing Sarcoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1650 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical trial studies genetic biomarkers from saliva samples in patients with Ewing sarcoma. Studying samples of saliva from patients with cancer in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Tumor Samples From Patients With Ewing Sarcoma

NCT00898053

Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor

COMPLETED

Biomarkers in Tissue Samples From Patients With Ewing Sarcoma

NCT01480518

Sarcoma

COMPLETED

Biomarker in Tissue Samples From Patients With Ewing Sarcoma

NCT01365949

Sarcoma

COMPLETED

Collecting and Storing Biological Samples From Patients With Ewing Sarcoma

NCT00899990

Askin Tumor Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor +1 more

COMPLETED

Diagnostic Study of Tumor Characteristics in Patients With Ewing's Sarcoma

NCT00048984

Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To determine the association between the length of Ewing sarcoma breakpoint region 1-Friend leukemia virus integration 1 (EWS-FLI1) fusion protein binding sites (microsatellites) and risk of Ewing's sarcoma (ES).

II. To determine the frequency and commonality of Caucasian ancestral markers in cases of ES self-identified as non-Caucasian (African-American, Asian, Hispanic).

III. To determine the association between genomic variants in ES-related genes and hernia development (i.e. the integrin signaling pathway) and risk of ES.

OUTLINE:

Genomic DNA is extracted from participants' saliva samples and analyzed for expression of EWS-FLI1 and other ES-target genes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

FAMILY_BASED

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ancillary-Correlative (genetic epidemiology of Ewing sarcoma)

Genomic DNA is extracted from participants' saliva samples and analyzed for expression of EWS-FLI1 and other ES-target genes.

laboratory biomarker analysis

Intervention Type OTHER

Correlative studies

questionnaire administration

Intervention Type OTHER

Ancillary studies

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

laboratory biomarker analysis

Correlative studies

Intervention Type OTHER

questionnaire administration

Ancillary studies

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The patient is enrolled on ACCRN07
* The patient has a diagnosis of Ewing Sarcoma (International Classification of Diseases \[ICD\] code morphology 9260; topography C40.0-C41.9, C76.0-C76.8, C80.9) and is registered with Children's Oncology Group (COG) by a North American member institution
* The patient must be diagnosed with Ewing sarcoma between December 24, 2007 and December 31, 2015
* The patient must have at least one biological parent alive and willing to participate
* All questionnaire respondents must understand English or Spanish
* Concomitant treatment on a therapeutic trial is not required

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes